웹2024년 11월 5일 · The primary objective of the study is to evaluate the safety and tolerability of BAT4306F in patients with CD20-positive B-cell lymphoma, when the injection dosage … 웹2024년 11월 17일 · A Phase I Clinical Trial of BAT4306F (for Injection) on Safety, Tolerability and Pharmacokinetics for Patients With CD20-positive, B-cell Non-Hodgkin's Lymphoma. …
BAT4306F / Bio-Thera Solutions
웹2024년 9월 1일 · The company said the money raised will go toward developing its core assets, including BAT4306F, an anti-CD20 therapy for treating B-cell non-Hodgkin lymphoma and other similar malignancies ... 웹2024년 12월 7일 · BAT4306F is being developed for use as a single agent and in combination with other agents for a variety of hematologic malignancies. About Bio-Thera Solutions. Bio … richard ndph
Phase 1 Non-Hodgkin
웹招股书显示,百奥泰的研发管线中,除了刚刚获批上市的bat1406,还有20个在研产品,其中4个产品(bat1706、bat8001、bat1806、bat2094)处于iii期临床研究阶段,1个产品(bat1306)属于ii期临床阶段,4个产品(bat8003、bat4306f、bat5906、bat2506)处于i期临床阶段,其他处于临床前研究阶段。 웹2024년 12월 7일 · Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that patient dosing has begun in a Phase I clinical study of BAT4306F in … 웹2024년 4월 20일 · 时隔一年,百奥泰再次决定冲刺港交所,所募集资金也主要用于核心产品研发及商业化,即bat4306f;bat1706;bat1706、bat1308;bat1806等产品,以及为潜在的策略性研发合作(包括联合开发及引进许可安排)提供资金。 richard n. costa phd psyd